Orforglipron vs Danuglipron | Research Comparison | QSC

Orforglipron vs Danuglipron: Research Comparison

Mechanism, clinical data, and research applications compared

Shop Both Compounds at QSC →

Factor Orforglipron Danuglipron
Drug Class Non-peptide GLP-1R agonist GLP-1R non-peptide small molecule
Route Oral once-daily SC weekly / oral
Phase 2/3 Result −14.7% (36 wks)* Phase 2 only (discontinued once-daily)
At QSC ✓ In Stock ✓ In Stock
Research Analysis: Both oral non-peptide GLP-1R agonists; orforglipron leads in Phase 3 results.
Research Use Only: All QSC products for in vitro laboratory research only. Not for human use.
Peptides
Orals
Oils
Search
Contact